Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Politically motivated crimes in Germany reached their highest level in 2023 since tracking began
BERLIN (AP) — Politically motivated crime in Germany last year reached its highest level since the g2024-05-22China's tourism booms during Qingming Festival holidays
China's consumption market during the just-ended Qingming Festival holidays showed better-than-expec2024-05-22- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-22
Xi Focus: Xi Urges Inner Mongolia to Pursue Green Development, Advance Chinese Modernization
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-22French Olympic fencer Thibus says she has been cleared of any wrongdoing after abnormal doping test
PARIS (AP) — Ysaora Thibus, one of France’s leading fencers, says she will be able to compete at the2024-05-22- The approaching Tomb Sweeping Day Festival, a period of ancestor worship, has become a popular touri2024-05-22
atest comment